{ "run": { "id": "cmnr14ckl04lup6582bx6rjt1", "region": "US", "assetId": "cmnr14cjq04lqp658jvc1zwze", "ticker": "JNJ", "snapshotId": "cmnr14ck404lsp658kbm9pwop", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:21:13.122Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr14ck404lsp658kbm9pwop", "assetId": "cmnr14cjq04lqp658jvc1zwze", "asOf": "2026-04-08T20:00:02.000Z", "snapshot": { "asOf": "2026-04-08T20:00:02.000Z", "quote": { "asOf": "2026-04-08T20:00:02.000Z", "open": null, "price": 241.3, "dayLow": 234.14, "volume": 6647942, "dayHigh": 241.32, "currency": "USD", "prevClose": 238.41, "week52Low": 141.5, "week52High": 251.71 }, "fundamentals": { "pe": 18.6486972147349, "beta": 0.213807105630391, "epsTTM": 11.13, "fcfTTM": 14376000000, "growth": { "epsYoy": 0.9058219178082194, "revenueYoy": 0.06048119251078011 }, "sector": "Pharmaceutical Preparations", "margins": { "net": 0.1198878554581461, "gross": 0.6901339504249923, "operating": 0.1994570780116595 }, "website": "https://www.jnj.com/", "industry": "Pharmaceutical", "pegRatio": 0.205875976812953, "ebitdaTTM": 41817000000, "forwardPe": 17.9861351819757, "marketCap": 367000000000, "totalCash": 19709000000, "totalDebt": 49938000000, "debtEquity": 0.612405572451682, "quickRatio": 0.6887632561061228, "revenueTTM": 22471000000, "companyName": "JOHNSON & JOHNSON", "priceToBook": 6.12773403316001, "currentRatio": 1.027676163027011, "dividendYield": 0.0247778606059082, "returnOnAssets": 0.01352341749912153, "returnOnEquity": 0.328705974688512, "analystOpinions": null, "businessSummary": "Johnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey, and publicly traded on the New York Stock Exchange. Its common stock is a component of the Dow Jones Industrial Average, and the company is ranked No. 48 on the 2025 Fortune 500 list of the largest United States corporations. In 2025, the company was ranked 42nd in the Forbes Global 2000. Johnson & Johnson has a global workforce of approximately 138,000 employees who are led by the company's current chairman and chief executive officer, Joaquin Duato. Johnson & Johnson is one of the world's most valuable companies and is one of only two U.S.-based companies that has a prime credit rating of AAA.", "enterpriseValue": 529908944000, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 140800, "sharesOutstanding": 2409898936, "enterpriseToEbitda": 12.67209374177966, "analystTargetMedian": null, "enterpriseToRevenue": 23.58190307507454, "operatingCashflowTTM": 24530000000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:21:13.108Z" }, "results": [ { "id": "cmnr14ckp04lwp658qa7914a6", "runId": "cmnr14ckl04lup6582bx6rjt1", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"JNJ\",\"currency\":\"USD\",\"current_price\":241.3,\"target_price_6m\":250,\"target_price_12m\":258,\"recommendation\":\"BUY\",\"confidence\":0.62,\"thesis_bullets\":[\"Post-Kenvue JNJ is a focused pharma/medtech platform with strong pipeline\",\"PEG ratio of 0.21 signals attractive growth-adjusted valuation\",\"90% EPS YoY growth reflects earnings recovery and operational leverage\",\"Dividend yield of ~2.5% adds total return floor for defensive investors\",\"Litigation overhang and patent cliffs cap near-term multiple expansion\"],\"key_drivers\":[{\"driver\":\"Pharmaceutical pipeline execution and new drug launches\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"MedTech segment organic growth acceleration\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Talc/opioid litigation resolution progress\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Patent cliffs on key drugs (Stelara biosimilar entry)\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Operational margin expansion post-Kenvue separation\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Strong AAA-rated balance sheet enables M&A optionality\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"FX headwinds from strong USD on international revenues\",\"impact\":\"LOW\",\"direction\":\"NEG\"},{\"driver\":\"Rising competitive pressure in immunology/oncology markets\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"Talc litigation could result in materially higher-than-expected settlements\",\"Stelara biosimilar competition accelerates revenue erosion faster than modeled\",\"Pipeline failures in late-stage clinical trials reduce growth visibility\",\"Tariff or pricing reform policies compress pharmaceutical margins\",\"Acquisition integration risk if JNJ pursues large-scale M&A\"],\"assumptions\":{\"revenue_cagr_3y\":0.05,\"ebit_margin_target\":0.28,\"wacc\":0.08,\"terminal_multiple\":18},\"scenarios\":{\"bear\":{\"target_price\":210,\"prob\":0.2,\"notes\":\"Litigation costs escalate and key patent cliffs erode earnings faster than expected.\"},\"base\":{\"target_price\":258,\"prob\":0.55,\"notes\":\"Steady mid-single-digit revenue growth with pipeline milestones supporting ~18x forward P/E.\"},\"bull\":{\"target_price\":290,\"prob\":0.25,\"notes\":\"Pipeline wins, MedTech acceleration, and litigation resolution drive multiple expansion to ~20x.\"}},\"method_notes\":\"Valuation anchored on forward P/E (17.99x snapshot) with implied forward EPS ~$13.4. Base 12M target applies ~19.2x on modestly growing EPS reflecting pipeline catalysts and margin improvement post-Kenvue. Bear case discounts for litigation/patent cliff risk; bull case adds pipeline upside. ~6.9% 12M price return supports BUY per rubric. Confidence moderate due to litigation uncertainty and patent cliff timing. Revenue snapshot appears partial; fundamental ratios used as-is per policy. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "ai-equity-research-v1", "risks": [ "Talc litigation could result in materially higher-than-expected settlements", "Stelara biosimilar competition accelerates revenue erosion faster than modeled", "Pipeline failures in late-stage clinical trials reduce growth visibility", "Tariff or pricing reform policies compress pharmaceutical margins", "Acquisition integration risk if JNJ pursues large-scale M&A" ], "ticker": "JNJ", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Steady mid-single-digit revenue growth with pipeline milestones supporting ~18x forward P/E.", "target_price": 258 }, "bear": { "prob": 0.2, "notes": "Litigation costs escalate and key patent cliffs erode earnings faster than expected.", "target_price": 210 }, "bull": { "prob": 0.25, "notes": "Pipeline wins, MedTech acceleration, and litigation resolution drive multiple expansion to ~20x.", "target_price": 290 } }, "confidence": 0.62, "assumptions": { "wacc": 0.08, "revenue_cagr_3y": 0.05, "terminal_multiple": 18, "ebit_margin_target": 0.28 }, "key_drivers": [ { "driver": "Pharmaceutical pipeline execution and new drug launches", "impact": "HIGH", "direction": "POS" }, { "driver": "MedTech segment organic growth acceleration", "impact": "MED", "direction": "POS" }, { "driver": "Talc/opioid litigation resolution progress", "impact": "HIGH", "direction": "POS" }, { "driver": "Patent cliffs on key drugs (Stelara biosimilar entry)", "impact": "HIGH", "direction": "NEG" }, { "driver": "Operational margin expansion post-Kenvue separation", "impact": "MED", "direction": "POS" }, { "driver": "Strong AAA-rated balance sheet enables M&A optionality", "impact": "MED", "direction": "POS" }, { "driver": "FX headwinds from strong USD on international revenues", "impact": "LOW", "direction": "NEG" }, { "driver": "Rising competitive pressure in immunology/oncology markets", "impact": "MED", "direction": "NEG" } ], "method_notes": "Valuation anchored on forward P/E (17.99x snapshot) with implied forward EPS ~$13.4. Base 12M target applies ~19.2x on modestly growing EPS reflecting pipeline catalysts and margin improvement post-Kenvue. Bear case discounts for litigation/patent cliff risk; bull case adds pipeline upside. ~6.9% 12M price return supports BUY per rubric. Confidence moderate due to litigation uncertainty and patent cliff timing. Revenue snapshot appears partial; fundamental ratios used as-is per policy. Not investment advice.", "current_price": 241.3, "recommendation": "BUY", "thesis_bullets": [ "Post-Kenvue JNJ is a focused pharma/medtech platform with strong pipeline", "PEG ratio of 0.21 signals attractive growth-adjusted valuation", "90% EPS YoY growth reflects earnings recovery and operational leverage", "Dividend yield of ~2.5% adds total return floor for defensive investors", "Litigation overhang and patent cliffs cap near-term multiple expansion" ], "target_price_6m": 250, "target_price_12m": 258 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 41806, "createdAt": "2026-04-09T05:21:13.122Z", "usage": { "inputTokens": 3695, "outputTokens": 1859, "costUsd": 0.06495 } }, { "id": "cmnr14ckp04lzp658z56jc5ld", "runId": "cmnr14ckl04lup6582bx6rjt1", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Research Model V1\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"JNJ\",\n \"currency\": \"USD\",\n \"current_price\": 241.3,\n \"target_price_6m\": 245.0,\n \"target_price_12m\": 250.0,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.6,\n \"thesis_bullets\": [\"Diversified healthcare portfolio with stable cash flows.\", \"AAA credit rating ensures strong financial health.\", \"Innovation pipeline drives long-term growth potential.\", \"Faces patent expirations and regulatory risks.\", \"Modest revenue growth offsets dividend stability.\"],\n \"key_drivers\": [\n {\"driver\": \"Pharmaceutical R&D success\", \"impact\": \"HIGH\", \"direction\": \"POS\"},\n {\"driver\": \"Medical device market demand\", \"impact\": \"MED\", \"direction\": \"POS\"},\n {\"driver\": \"Dividend yield and payout\", \"impact\": \"LOW\", \"direction\": \"POS\"},\n {\"driver\": \"Economic downturn sensitivity\", \"impact\": \"MED\", \"direction\": \"NEG\"},\n {\"driver\": \"Patent cliff expirations\", \"impact\": \"HIGH\", \"direction\": \"NEG\"},\n {\"driver\": \"Regulatory approval timelines\", \"impact\": \"HIGH\", \"direction\": \"POS\"},\n {\"driver\": \"Currency exchange fluctuations\", \"impact\": \"LOW\", \"direction\": \"NEG\"}\n ],\n \"risks\": [\"Clinical trial failures for new drugs.\", \"Legal liabilities from litigation.\", \"Healthcare policy changes impacting pricing.\", \"Increased competition from generics.\"],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.05,\n \"ebit_margin_target\": 0.20,\n \"wacc\": 0.07,\n \"terminal_multiple\": 12.5\n },\n \"scenarios\": {\n \"bear\": {\"target_price\": 220.0, \"prob\": 0.2, \"notes\": \"Slower growth and high litigation costs reduce earnings.\"},\n \"base\": {\"target_price\": 250.0, \"prob\": 0.6, \"notes\": \"Steady execution with moderate revenue increases.\"},\n \"bull\": {\"target_price\": 280.0, \"prob\": 0.2, \"notes\": \"Successful drug launches and market expansion boost performance.\"}\n },\n \"method_notes\": \"Used DCF with industry comps; HOLD due to fair valuation (3.6% upside) and mixed evidence. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI Equity Research Model V1", "risks": [ "Clinical trial failures for new drugs.", "Legal liabilities from litigation.", "Healthcare policy changes impacting pricing.", "Increased competition from generics." ], "ticker": "JNJ", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Steady execution with moderate revenue increases.", "target_price": 250 }, "bear": { "prob": 0.2, "notes": "Slower growth and high litigation costs reduce earnings.", "target_price": 220 }, "bull": { "prob": 0.2, "notes": "Successful drug launches and market expansion boost performance.", "target_price": 280 } }, "confidence": 0.6, "assumptions": { "wacc": 0.07, "revenue_cagr_3y": 0.05, "terminal_multiple": 12.5, "ebit_margin_target": 0.2 }, "key_drivers": [ { "driver": "Pharmaceutical R&D success", "impact": "HIGH", "direction": "POS" }, { "driver": "Medical device market demand", "impact": "MED", "direction": "POS" }, { "driver": "Dividend yield and payout", "impact": "LOW", "direction": "POS" }, { "driver": "Economic downturn sensitivity", "impact": "MED", "direction": "NEG" }, { "driver": "Patent cliff expirations", "impact": "HIGH", "direction": "NEG" }, { "driver": "Regulatory approval timelines", "impact": "HIGH", "direction": "POS" }, { "driver": "Currency exchange fluctuations", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Used DCF with industry comps; HOLD due to fair valuation (3.6% upside) and mixed evidence. Not investment advice.", "current_price": 241.3, "recommendation": "HOLD", "thesis_bullets": [ "Diversified healthcare portfolio with stable cash flows.", "AAA credit rating ensures strong financial health.", "Innovation pipeline drives long-term growth potential.", "Faces patent expirations and regulatory risks.", "Modest revenue growth offsets dividend stability." ], "target_price_6m": 245, "target_price_12m": 250 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 356, "createdAt": "2026-04-09T05:21:13.122Z", "usage": { "inputTokens": 2206, "outputTokens": 2768, "costUsd": 0.00178 } }, { "id": "cmnr14ckp04lxp6586vuxoqs9", "runId": "cmnr14ckl04lup6582bx6rjt1", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"EquityResearch_JNJ_v2\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"JNJ\",\n \"currency\": \"USD\",\n \"current_price\": 241.3,\n \"target_price_6m\": 250.0,\n \"target_price_12m\": 258.0,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.7,\n \"thesis_bullets\": [\n \"Defensive profile with 0.21 beta offers stability amid macroeconomic uncertainty.\",\n \"Solid 6% revenue growth driven by Innovative Medicine and MedTech segments.\",\n \"Strong ROE of 32.8% highlights efficient capital allocation and profitability.\",\n \"Talc litigation remains an overhang, though largely priced into current valuation.\",\n \"Attractive 2.48% dividend yield provides a reliable income floor for investors.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Innovative Medicine pipeline\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"MedTech procedure volumes\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Talc litigation liabilities\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Stelara biosimilar competition\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Capital allocation and M&A\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Macro healthcare utilization\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Higher-than-expected talc litigation settlement costs.\",\n \"Faster erosion of Stelara market share due to biosimilars.\",\n \"Regulatory pricing pressures from the Inflation Reduction Act (IRA).\",\n \"Slower recovery in global MedTech procedure volumes.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.045,\n \"ebit_margin_target\": 0.28,\n \"wacc\": 0.075,\n \"terminal_multiple\": 16.0\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 215.0,\n \"prob\": 0.2,\n \"notes\": \"Talc litigation settlements exceed reserves and generic competition erodes key drug sales.\"\n },\n \"base\": {\n \"target_price\": 262.0,\n \"prob\": 0.6,\n \"notes\": \"Steady growth in MedTech and pharma pipeline offsets Stelara declines and legal costs.\"\n },\n \"bull\": {\n \"target_price\": 290.0,\n \"prob\": 0.2,\n \"notes\": \"Favorable talc resolution and faster-than-expected uptake of new pharmaceutical launches.\"\n }\n },\n \"method_notes\": \"Valuation based on a 10-year DCF and sum-of-the-parts analysis. The probability-weighted scenario target implies a ~7% return, supporting a BUY recommendation. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "EquityResearch_JNJ_v2", "risks": [ "Higher-than-expected talc litigation settlement costs.", "Faster erosion of Stelara market share due to biosimilars.", "Regulatory pricing pressures from the Inflation Reduction Act (IRA).", "Slower recovery in global MedTech procedure volumes." ], "ticker": "JNJ", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Steady growth in MedTech and pharma pipeline offsets Stelara declines and legal costs.", "target_price": 262 }, "bear": { "prob": 0.2, "notes": "Talc litigation settlements exceed reserves and generic competition erodes key drug sales.", "target_price": 215 }, "bull": { "prob": 0.2, "notes": "Favorable talc resolution and faster-than-expected uptake of new pharmaceutical launches.", "target_price": 290 } }, "confidence": 0.7, "assumptions": { "wacc": 0.075, "revenue_cagr_3y": 0.045, "terminal_multiple": 16, "ebit_margin_target": 0.28 }, "key_drivers": [ { "driver": "Innovative Medicine pipeline", "impact": "HIGH", "direction": "POS" }, { "driver": "MedTech procedure volumes", "impact": "MED", "direction": "POS" }, { "driver": "Talc litigation liabilities", "impact": "HIGH", "direction": "NEG" }, { "driver": "Stelara biosimilar competition", "impact": "HIGH", "direction": "NEG" }, { "driver": "Capital allocation and M&A", "impact": "MED", "direction": "POS" }, { "driver": "Macro healthcare utilization", "impact": "MED", "direction": "POS" } ], "method_notes": "Valuation based on a 10-year DCF and sum-of-the-parts analysis. The probability-weighted scenario target implies a ~7% return, supporting a BUY recommendation. Not investment advice.", "current_price": 241.3, "recommendation": "BUY", "thesis_bullets": [ "Defensive profile with 0.21 beta offers stability amid macroeconomic uncertainty.", "Solid 6% revenue growth driven by Innovative Medicine and MedTech segments.", "Strong ROE of 32.8% highlights efficient capital allocation and profitability.", "Talc litigation remains an overhang, though largely priced into current valuation.", "Attractive 2.48% dividend yield provides a reliable income floor for investors." ], "target_price_6m": 250, "target_price_12m": 258 }, "errorsJson": { "attempts": [ { "error": "sanity_error: buy_scenario_return_too_low: BUY requires >= 6% return from probability-weighted scenarios.", "attempt": 0, "rawOutputTruncated": "{\n \"model\": \"EquityResearch_JNJ_v1\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"JNJ\",\n \"currency\": \"USD\",\n \"current_price\": 241.3,\n \"target_price_6m\": 250.0,\n \"target_price_12m\": 258.0,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.7,\n \"thesis_bullets\": [\n \"Defensive profile with 0.21 beta offers stability amid macroeconomic uncertainty.\",\n \"Solid 6% revenue growth driven by Innovative Medicine and MedTech segments.\",\n \"Strong ROE of 32.8% highlights efficient capital allocation and profitability.\",\n \"Talc litigation remains an overhang, though largely priced into current valuation.\",\n \"Attractive 2.48% dividend yield provides a reliable income floor for investors.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Innovative Medicine pipeline\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"MedTech procedure volumes\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Talc litigation liabilities\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Stelara biosimilar competition\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Capital allo…" } ], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 24015, "createdAt": "2026-04-09T05:21:13.122Z", "usage": { "inputTokens": 3305, "outputTokens": 816, "costUsd": 0.016402 } }, { "id": "cmnr14ckp04lvp6582uy3vlnr", "runId": "cmnr14ckl04lup6582bx6rjt1", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"AI Model Recommendation v2\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"JNJ\",\"currency\":\"USD\",\"current_price\":241.3,\"target_price_6m\":248,\"target_price_12m\":254,\"recommendation\":\"HOLD\",\"confidence\":0.61,\"thesis_bullets\":[\"Defensive pharma-medtech mix supports resilient cash flow and dividends.\",\"Low beta and AAA balance sheet reduce downside in volatile markets.\",\"Current valuation near fair at 18.6x TTM earnings limits rerating upside.\",\"Recent EPS and revenue growth are solid but likely normalize.\",\"Litigation, patent cliffs, and device execution keep risk-reward balanced.\"],\"key_drivers\":[{\"driver\":\"Innovative Medicine launches\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"MedTech procedure demand\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Cash flow durability\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Balance sheet flexibility\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Litigation overhang\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Patent loss exposure\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Pricing and FX pressure\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Dividend support\",\"impact\":\"LOW\",\"direction\":\"POS\"}],\"risks\":[\"Adverse talc or other litigation outcomes\",\"Major drug LOE faster than expected\",\"Regulatory setbacks or trial failures\",\"Procedure softness or hospital budget pressure\"],\"assumptions\":{\"revenue_cagr_3y\":0.045,\"ebit_margin_target\":0.245,\"wacc\":0.075,\"terminal_multiple\":16.5},\"scenarios\":{\"bear\":{\"target_price\":210,\"prob\":0.25,\"notes\":\"Litigation costs rise and growth slows toward low single digits.\"},\"base\":{\"target_price\":254,\"prob\":0.5,\"notes\":\"Steady pharma and medtech execution supports modest earnings growth.\"},\"bull\":{\"target_price\":285,\"prob\":0.25,\"notes\":\"Pipeline execution and margin recovery drive a higher multiple.\"}},\"method_notes\":\"Blend of forward earnings and EV/EBITDA anchored to snapshot profitability and cash flow. Hold reflects near-fair value with modest upside versus meaningful litigation and LOE risk. Snapshot quote fields kept authoritative; some fundamental fields appear internally inconsistent, increasing uncertainty. not investment advice\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI Model Recommendation v2", "risks": [ "Adverse talc or other litigation outcomes", "Major drug LOE faster than expected", "Regulatory setbacks or trial failures", "Procedure softness or hospital budget pressure" ], "ticker": "JNJ", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Steady pharma and medtech execution supports modest earnings growth.", "target_price": 254 }, "bear": { "prob": 0.25, "notes": "Litigation costs rise and growth slows toward low single digits.", "target_price": 210 }, "bull": { "prob": 0.25, "notes": "Pipeline execution and margin recovery drive a higher multiple.", "target_price": 285 } }, "confidence": 0.61, "assumptions": { "wacc": 0.075, "revenue_cagr_3y": 0.045, "terminal_multiple": 16.5, "ebit_margin_target": 0.245 }, "key_drivers": [ { "driver": "Innovative Medicine launches", "impact": "HIGH", "direction": "POS" }, { "driver": "MedTech procedure demand", "impact": "MED", "direction": "POS" }, { "driver": "Cash flow durability", "impact": "HIGH", "direction": "POS" }, { "driver": "Balance sheet flexibility", "impact": "MED", "direction": "POS" }, { "driver": "Litigation overhang", "impact": "HIGH", "direction": "NEG" }, { "driver": "Patent loss exposure", "impact": "HIGH", "direction": "NEG" }, { "driver": "Pricing and FX pressure", "impact": "MED", "direction": "NEG" }, { "driver": "Dividend support", "impact": "LOW", "direction": "POS" } ], "method_notes": "Blend of forward earnings and EV/EBITDA anchored to snapshot profitability and cash flow. Hold reflects near-fair value with modest upside versus meaningful litigation and LOE risk. Snapshot quote fields kept authoritative; some fundamental fields appear internally inconsistent, increasing uncertainty. not investment advice", "current_price": 241.3, "recommendation": "HOLD", "thesis_bullets": [ "Defensive pharma-medtech mix supports resilient cash flow and dividends.", "Low beta and AAA balance sheet reduce downside in volatile markets.", "Current valuation near fair at 18.6x TTM earnings limits rerating upside.", "Recent EPS and revenue growth are solid but likely normalize.", "Litigation, patent cliffs, and device execution keep risk-reward balanced." ], "target_price_6m": 248, "target_price_12m": 254 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_09f501cbae0ac7420069d75a7335e48195aac92ea843b981af", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 30623, "createdAt": "2026-04-09T05:21:13.122Z", "usage": { "inputTokens": 2470, "outputTokens": 1717, "costUsd": 0.028361 } }, { "id": "cmnr14ckp04lyp6582r21nnpo", "runId": "cmnr14ckl04lup6582bx6rjt1", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Research Model\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"JNJ\",\n \"currency\": \"USD\",\n \"current_price\": 241.3,\n \"target_price_6m\": 255,\n \"target_price_12m\": 270,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"Stable healthcare demand supports consistent revenue growth\",\n \"Robust free cash flow enables shareholder returns\",\n \"Low PEG ratio signals undervaluation vs peers\",\n \"Litigation settlements pressure near-term earnings\",\n \"Innovative drug pipeline offers significant upside potential\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Pharma innovation pipeline\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Legal and litigation risks\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"MedTech segment recovery\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Patent expirations on drugs\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Dividend yield consistency\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Low beta stability\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Global FX and macro\",\n \"impact\": \"LOW\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"M&A opportunities\",\n \"impact\": \"LOW\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Further talc and opioid litigation costs\",\n \"Key product patent expirations\",\n \"Regulatory hurdles on drug pricing\",\n \"Biosimilar competition in oncology\",\n \"Supply chain disruptions\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.05,\n \"ebit_margin_target\": 0.24,\n \"wacc\": 0.075,\n \"terminal_multiple\": 19\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 215,\n \"prob\": 0.3,\n \"notes\": \"Escalating litigation and pipeline delays cause de-rating.\"\n },\n \"base\": {\n \"target_price\": 270,\n \"prob\": 0.5,\n \"notes\": \"Steady 5% growth, margin expansion, and legal resolution.\"\n },\n \"bull\": {\n \"target_price\": 315,\n \"prob\": 0.2,\n \"notes\": \"Accelerated approvals and strong MedTech lift multiples.\"\n }\n },\n \"method_notes\": \"DCF using 5% revenue CAGR, 24% EBIT margin target, 7.5% WACC and 19x terminal. Low PEG and cash flow strength offset litigation risks yielding BUY. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI Equity Research Model", "risks": [ "Further talc and opioid litigation costs", "Key product patent expirations", "Regulatory hurdles on drug pricing", "Biosimilar competition in oncology", "Supply chain disruptions" ], "ticker": "JNJ", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Steady 5% growth, margin expansion, and legal resolution.", "target_price": 270 }, "bear": { "prob": 0.3, "notes": "Escalating litigation and pipeline delays cause de-rating.", "target_price": 215 }, "bull": { "prob": 0.2, "notes": "Accelerated approvals and strong MedTech lift multiples.", "target_price": 315 } }, "confidence": 0.62, "assumptions": { "wacc": 0.075, "revenue_cagr_3y": 0.05, "terminal_multiple": 19, "ebit_margin_target": 0.24 }, "key_drivers": [ { "driver": "Pharma innovation pipeline", "impact": "HIGH", "direction": "POS" }, { "driver": "Legal and litigation risks", "impact": "HIGH", "direction": "NEG" }, { "driver": "MedTech segment recovery", "impact": "MED", "direction": "POS" }, { "driver": "Patent expirations on drugs", "impact": "MED", "direction": "NEG" }, { "driver": "Dividend yield consistency", "impact": "MED", "direction": "POS" }, { "driver": "Low beta stability", "impact": "MED", "direction": "POS" }, { "driver": "Global FX and macro", "impact": "LOW", "direction": "NEG" }, { "driver": "M&A opportunities", "impact": "LOW", "direction": "POS" } ], "method_notes": "DCF using 5% revenue CAGR, 24% EBIT margin target, 7.5% WACC and 19x terminal. Low PEG and cash flow strength offset litigation risks yielding BUY. Not investment advice.", "current_price": 241.3, "recommendation": "BUY", "thesis_bullets": [ "Stable healthcare demand supports consistent revenue growth", "Robust free cash flow enables shareholder returns", "Low PEG ratio signals undervaluation vs peers", "Litigation settlements pressure near-term earnings", "Innovative drug pipeline offers significant upside potential" ], "target_price_6m": 255, "target_price_12m": 270 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "18833441-f0ba-9b12-9211-30589f386c4c", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 22333, "createdAt": "2026-04-09T05:21:13.122Z", "usage": { "inputTokens": 2810, "outputTokens": 3881, "costUsd": 0.066645 } } ] } }